Who is sponsoring NCT01348763?

NCT01348763 is sponsored by Imperial College London.

What drugs are being tested in NCT01348763?

Interventions: Maraviroc, Truvada, Darunavir.

What is the status of NCT01348763?

NCT01348763 is currently COMPLETED.

Last reviewed 2019-10-08 · How we verify

A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects

NCT01348763 Phase 1 COMPLETED Results posted

This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.

Details

Lead sponsor	Imperial College London
Phase	Phase 1
Status	COMPLETED
Enrolment	13
Start date	2011-10
Completion	2012-05

Conditions

Interventions

Maraviroc
Truvada
Darunavir

Primary outcomes

The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day — 10 day, 20 days
On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured .

Countries

United Kingdom